Related Experiment Video
Updated: Feb 8, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
A Galligan1, W Xu2, S Fourlanos1
1Department of Diabetes and Endocrinology, Royal Melbourne Hospital.
Background:
In recent years, immune checkpoint blockade has become a standard therapy for a wide range of cancers. Adverse events including endocrinopathies result from the induction of autoimmunity.
Case Report:
We report a case series of nine individuals who presented with immunotherapy-induced type 1 diabetes between 2015-2017.
Discussion:
Onset of diabetes occurred within 12 weeks of commencing therapy. Anti- GAD antibodies were present in six people. Retrospective testing of islet antibodies in pre-treatment samples was possible in two people and this revealed anti-GAD seroconversion in the first and high anti-GAD titres pre and post-treatment in the second person. Six people had high risk HLA haplotypes. Clinical and genetic factors are described and compared with previously published cases. This article is protected by copyright. All rights reserved.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Self-Presentation: Self-Monitoring and Self-Handicapping
Self-Presentation
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Strategies of Self-Presentation I: Strategic Self-Presentation
Processes of Self-Presentation

